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Abstract
Probiotics, specifically Bifidobacteria, may improve abdominal pain in patients with irritable bowel syndrome (IBS); however,
results from randomised controlled trials (RCTs) are conflicting. Here, we systematically reviewed the efficacy of Bifidobacteria
on abdominal pain in IBS. We searchedMEDLINE, EMBASE and the Cochrane Controlled Trials Register from inception to 20
May 2019, without language or date restrictions. The search strategy comprised of the combination of three concepts: supple-
mentation, abdominal pain, and IBS. Inclusion criteria included double-blind placebo-controlled RCTs featuring Bifidobacteria
supplementation in Rome-diagnosed IBS patients. A total of 8 RCTs involving a total of 1045 patients with Rome diagnosed IBS
were included. The dose of total Bifidobacteria ranged from 106 to > 1011 cfu (colony-forming unit) and duration of supple-
mentation ranged between 2 and 8 weeks. Bifidobacteria was delivered through either intake of fermented milk products,
encapsulation or via a malted milk beverage, with all studies assessing abdominal pain via a visual analogue Likert scale.
From the studies included, 50% (n = 4) of studies found a statistically significant improvement in abdominal pain following
Bifidobacteria supplementation compared to placebo, 38% (n = 3) of studies found non-significant improvements and 12% (n =
1) showed a statistically significant dose-response effect of improvement. The evidence shows a heterogeneity of effect for
Bifidobacteria dependent upon strain, dosage and delivery method. While not all studies demonstrate significant improvements
in abdominal pain, none of the selected studies reported an increase in pain or other adverse effects.
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Introduction
Irritable bowel syndrome (IBS) is one of the most widely
recognised functional bowel disorders globally, characterised
by chronic or recurrent abdominal pain [1]. While it is a com-
mon condition, the aetiology is not fully understood. However,
classical hallmarks include disturbances in gut microbiota, low-
grade mucosal inflammation, immune activation and altered
intestinal permeability [2]. Probiotics, which are live microbial
supplements that colonise in the colon and serve to modulate
the intestinal microbial-inflammatory-immunological milieu,
have been shown to yield beneficial effects on both the clinical
course and symptoms of IBS [3, 4]. Probiotics are numerous
and exert divergent effects depending upon the unique charac-
teristics of their composition, namely, their genus, species and
strain [5]; while some probiotics display a desired anti-
inflammatory effect, others principally impact motility [6] and
visceral sensation [7]. Thus, the efficacy of probiotic supple-
mentation on reducing symptoms of IBS is largely dependent
upon, and specific to, the individual probiotic used.
Much of the research has investigated the impact of composite
probiotic mixtures containing several strains of Lactobacillus,
Bifidobacterium and Propionibacterium, which hampers the as-
sessment of specific strains in relieving IBS symptoms. In IBS,
patients typically present with significantly lower levels of
Bifidobacteria in faecal and duodenal mucosa samples, yet other
major bacterial groups remain preserved [4]. Evidence suggests
that Bifidobacteria supplementation, which serves to restore a
balanced microbial composition, modulates immune function,
gut microbiota and intestinal mucosal adhesion in IBS patients
[8], with studies demonstrating positive effects on epithelial cell
adherence, reinforcement of tight junctions, stimulation of IgA
production and cell-mediated immunity, which are impaired in
IBS patients [9, 10]. Based on these promising findings, clinical
trials have been conducted to establish whether Bifidobacteria
supplementation reduces abdominal pain in IBS; however,
* Matthew D. Campbell
m.d.campbell@leeds.ac.uk
1 School of Food Science and Nutrition, University of Leeds,
Leeds, UK
Probiotics and Antimicrobial Proteins
https://doi.org/10.1007/s12602-019-09609-7
results are conflicting. Therefore, this investigation aimed to sys-
tematically review human studies in which the efficacy of
Bifidobacteria supplementation had been examined as a treat-
ment for abdominal pain in IBS.
Methods
This systematic review was conducted in accordance with
PRISMA (Preferred Reporting Items for Systematic
Reviews and Meta-analyses) guidelines [11] and prospective-
ly registered. A search of the medical literature was conducted
using MEDLINE, EMBASE and the Cochrane Controlled
Trials Register from inception to 20 May 2019, without lan-
guage or date restrictions, for all RCTs investigating the im-
pact of Bifidobacteria on abdominal pain in patients with IBS.
The search strategy comprised of the combination of three
concepts: supplementation, abdominal pain and IBS. For
these three items, relevant keyword variations were used,
which included keyword variations in the controlled vocabu-
laries of the different databases, as well as free text word
variations. Inclusion criteria included double-blind placebo-
controlled RCTs featuring Bifidobacteria supplementation in
Rome-diagnosed IBS patients.
Two investigators (CP and MDC) independently reviewed
all RCTs by title and abstract and subsequently by full-text
evaluation. Any disagreements were resolved through arbitra-
tions with a third researcher independent from the research
team. If relevant study information was missing, authors were
contacted, and foreign language manuscripts translated where
necessary. The bibliographies of all identified studies were
used to perform a recursive search of the literature. The quality
of the articles was assessed by the two independent reviewers
according to the levels of evidence and the recommendations
used for good clinical practice [12]. Risk of bias was assessed
using the Cochrane Collaboration Risk of Bias tool. Each
RCT was given one of three rankings, ‘high risk’, ‘low risk’,
or ‘unknown risk’, in each of the following domains: sequence
generation, allocation concealment, blinding of participants
and personnel, blinding of outcome assessors, incomplete da-
ta, selective outcome reporting, and other sources of bias.
Discrepancies which arose during this process were resolved
firstly by discussion then by a third independent researcher
where necessary. Risk of bias outcomes is presented within
Supplement 1, Table 1.
Results
In total, 343 records were identified through database screen-
ing, of these 8 RCTs were eligible and included in this review
(Fig. 1; Table 1). A total of 1045 adults aged between 20 and
75 years with Rome-diagnosed IBSwere included. The ranges
of doses of total Bifidobacteria were 106 to > 1011 cfu and
duration of supplementation between 2 and 8 weeks.
Bifidobacteria was delivered through either intake
of fermented milk products (n = 3) [13, 16, 17], encapsulation
(n = 4) [10, 14, 15, 18], or via a malted milk beverage (n = 1)
[6], with all studies assessing abdominal pain via a visual
analogue Likert scale.
From the studies included, 50% (n = 4) of studies found a
statistically significant improvement in abdominal pain fol-
lowing Bifidobacteria supplementation compared to placebo,
38% (n = 3) of studies found non-significant improvements,
and 12% (n = 1) showed a statistically significant dose-
response effect of improvement (Table 1).
Enriched Fermented Milk Products
Agrawal and colleagues [13] investigated trialled
Bifidobacterium lactis in a fermented milk product consumed
daily over a 4-week intervention compared to a daily
probiotic-naive placebo non-fermented product. Individuals
under the treatment condition were found to have significantly
lower levels of abdominal pain compared to the control group.
Guyonnet and colleagues [16] investigated the effect of
Bifidobacterium animalis in a yoghurt compared to a placebo
heat-treated yoghurt. Abdominal pain improved equally in
both the treatment and placebo group overtime at 3 and 6
weeks compared to baseline; no conditional differences be-
tween treatment and placebo were evident. Similarly, Min
and colleagues [17] investigated the use of daily intake of
yoghurt enriched with Bifidobacterium animalis subspecies
lactis. This placebo-controlled trial compared symptoms of
abdominal pain following an 8-week treatment phase and
failed to yield statistically significant benefits. Of note, the
placebo in this trial consisted of a traditional yoghurt, which
is likely to contain traces of Bifidobacteria, albeit in signifi-
cantly lower amounts, which may account for the null effects
on abdominal pain between the two conditions. Furthermore,
the interventional treatment contained acacia gum, a complex
indigestible polysaccharide fermented in the colon, which
may confound potential improvements in abdominal pain
resulting from Bifidobacteria alone.
Encapsulation
Guglielmetti and colleagues [15] trialled daily encapsulat-
ed delivery of Bifidobacterium bifidum against a placebo
control over a 4-week treatment period. The authors ob-
served significant time-course reductions in subjective ab-
dominal pain from weeks 1 to 4, which persisted into the
subsequent 2-week washout period. Charbonneau et al.
[14] investigated the effect of encapsulated delivery of
daily Bifidobacterium longum subspecies infantis over
an 8-week period and reported reduced levels of
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perceived abdominal pain at the end of the supplementa-
tion period. Similarly, these findings are supported by
those of Biviano et al. [10] in which 2-week daily supple-
mentation of Bifidobacterium longum and Lactoferrin was
trialled, resulting in a significant reduction in pain scores
in the treatment group compared to control. Of note, this
s t u d y i n c l u d e d L a c t o f e r r i n , a p r e b i o t i c f o r
Bifidobacterium into the treatment product; further re-
search is needed to establish whether the Lactoferrin in
addition to Bifidobacterium in isolation carries any addi-
tive effect on abdominal pain or adjunct effects on other
symptoms of IBS. Whorwell et al. [18] investigated the
dose-response of encapsulated Bifidobacterium infantis
supplementation whereby subjects were randomly allocat-
ed to receiving either a daily capsule of Bifidobacterium
infantis at a dosage of 1 × 106, 1 × 108 or 1 × 1010 cfu or
placebo control for 4 weeks. The authors reported a
beneficial treatment effect for Bifidobacterium infantis at
a dosage of 1 × 108 cfu which persisted throughout the
subsequent two-week washout period, while dosages of 1
× 106 or 1 × 1010 cfu did not yield significant reductions
in abdominal pain.
Malted Milk Beverage
O’Mahony and colleagues [6] investigated the impact of
Bifidobacteria infantis on abdominal pain delivered
through a daily malted milk beverage over a course of 8
weeks. Significant time course improvements were ob-
served following treatment, with improvements in abdom-
inal pain evident at week-1, peaking at week-2, with a
sustained suppression of symptoms up to trial cessation
at 8 weeks.
Fig. 1 Flowchart of trial selection
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Discussion
There is conflicting evidence regarding the clinical utility of
probiotics, specifically Bifidobacteria, in reducing subjective
abdominal pain in patients with IBS. Our systematic review
provides the most comprehensive and contemporary review to
date assessing the impact of Bifidobacteria on abdominal pain
in patients with IBS. Considering the cumulative findings
from 8 RCTs with a total of 1045 adults with IBS, we con-
clude that evidence shows a heterogeneity of effect for
Bifidobacteria dependent upon strain, dosage and delivery
method. Importantly, while not all studies demonstrate a sta-
tistically significant improvement in abdominal pain, none of
the selected studies in this review reported an increase in pain
or other adverse effects compared to placebo.
Irritable bowel syndrome (IBS) is one of the most widely
recognised functional bowel disorders globally, characterised
by chronic or recurrent abdominal pain [1]. In the UK, ~ 17%
of the general population live with IBS, and up to 50% of all
general practitioner (GP) visits for gastrointestinal distur-
bances relate to IBS symptoms [19]. IBS poses a significant
personal, societal and economic burden [20–22], thus clinical-
ly effective and pragmatic treatment options which serve to
reduce the symptoms of IBS are much needed. Although sev-
eral reviews have previously concluded that probiotics im-
prove IBS symptoms including abdominal pain [23–28],
many reviews feature studies investigating the use of compos-
ite probiotic mixtures containing several strains of
Lactobacillus, Bifidobacterium and Propionibacterium,
which hampers the assessment of specific strains in relieving
IBS symptoms. As such, this is the first study to systematically
review the clinical effectiveness of single strains of
Bifidobacterium on symptomatic abdominal pain in patients
with IBS. Despite applying stringent inclusion criteria and
rigorous methodology, there are several concerns regarding
the quality of available evidence. Firstly, the available litera-
ture lacks uniformity in the Bifidobacterium species tested and
the dosage used. From the investigations reviewed in this
study, three differing strains of Bifidobacteria were sampled,
and dosages varied from 106 to > 1011 cfu. Secondly, the
delivery of the probiotics varied between studies, including
delivery via fermented milk products [13, 16, 17], a malted
milk beverage [6] or via encapsulation [10, 14, 15, 18].
Thirdly, treatment periods varied from 2 weeks to 8 weeks
with variable washout periods; considering the intermittent
nature of symptomatic IBS abdominal pain, short treatment
durations and short observation windows may fail to ade-
quately capture the effect, and legacy effect, of supplementa-
tion or severity of symptoms. Fourthly, the composition of
placebos used in some studies may confound study findings
[10, 17]. In future studies, it would be helpful to stratify IBS
patients by clinical presentation and/or by severity of symp-
toms, and include longer treatment durations and longer wash-
out periods to establish long-term legacy effects and whether
dosages can be taken less frequently.
Currently, the evidence shows a heterogeneity of effect for
Bifidobacteria on abdominal pain in IBS dependent upon
strain, dosage and delivery method. Future research should
consider investigating whether divergent treatment responses
are determined by supplementation characteristics (strain,
dosage and delivery method), as well as individual clinical
parameters which may influence treatment effectiveness (e.g.
gut microbiota composition, gut motility), and whether these
clinical parameters are useful tools for predicting treatment
outcomes. This review should help others obtaining a bal-
anced view of the relevant literature available. Presently, it is
difficult to strongly advocate the use of Bifidobacteria for
reducing abdominal pain in IBS; however, as none of the
selected studies in this review reported an increase in pain or
other adverse effects, we can at least have a greater degree of
confidence in remarking that Bifidobacteria supplementation
is unlikely to have an adverse effect.
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